The phase 3 clinical trial, published recently in JAMA Oncology and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer associated with asbestos exposure and which has limited therapeutic options.